美国

我们是谁

  • 4 月 5, 2022
    利用 CRISPR 基因工程抑制编码细胞内免疫检查点 CISH 基因的肿瘤浸润淋巴细胞治疗转移性胃肠癌的研究
  • 4 月 5, 2022
    一项针对晚期实体瘤患者的BMS-986340单药及与Nivolumab联合用药研究
  • 4 月 5, 2022
    Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery
  • 4 月 5, 2022
    Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
  • 4 月 5, 2022
    A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
  • 4 月 5, 2022
    Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
  • 4 月 5, 2022
    治疗寡转移性实体瘤患者的全身疗法与局部巩固疗法
  • 4 月 5, 2022
    Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
  • 4 月 5, 2022
    Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
  • 4 月 5, 2022
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery